


“FAVIPIRAVIR” A NEW PROMISE IN THE COVID-19 TREATMENT

Drug firm Glenmark pharmaceuticals, under the brand name Fabiflu, has launched an antiviral drug Favipiravir, to cure patients with mild to moderate covid cases.



Glenmark has received manufacturing and marketing approval from India’s drug regulator, making Fabiflu the first oral favipiravir approved medication in India for treatment of covid-19. It was back on Friday (June 19), when the company received the seal of approval of manufacturing and marketing of the drug from the Drugs Controller General of India (DCGI)

The antiviral offers broad spectrum RNA virus coverage with clinical improvement noted across age groups 20 to 90 years. Favipiravir can be used in Covid-19 symptoms. It has shown clinical improvement of up to 88% in Covid-19 mild to moderate Covid-19 cases. The medication will be available in the form of a 200 mg tablet. Each tablet of 200 mg costs Rs.103 and strip containing 34 tablets has been priced at

Rs.3500.Clinical trial is on for 150 patients in India. Once administered the drug will help in bringing down the viral load on the patient. Inhibits the activity of Viral RNA-Dependent RNA Polymerase (of Noval Corona Virus)

Favipiravir has been used in Russia, Japan and China to treat such patients and has been proved successful. The drug will be under restricted use, which means it can be consumed only under doctor's guidance and supervision.

**Review done by; Sruthi s, Parvathy s, Suveenachandran,
Stellypaul. 1st year D.pharm**

Reference: The Hindu dated 20th June 2020

